Sanofi, Google team up to discover better treatments

Published On 2019-06-23 03:35 GMT   |   Update On 2021-08-13 11:56 GMT




Sanofi and Google will use data sets to improve their understanding of key diseases and extract patients' insights and feedback, the companies said in a joint statement.

U.S: French healthcare company Sanofi has teamed up with Google to work on innovations, aimed at using emerging data technologies to change how medicines and health services will be delivered in future.

Sanofi and Google will use data sets to improve their understanding of key diseases and extract patients' insights and feedback, the companies said in a joint statement.

Read Also: Sanofi to Partner with Google to use AI, Deep Analytics to find better treatments

"Combining Sanofi's biologic innovations and scientific data with Google's industry-leading capabilities, from cloud computing to state-of-the-art artificial intelligence, we aspire to give people more control over their health and accelerate the discovery of new therapies," said Ameet Nathwani, chief medical officer and executive vice-president, Sanofi.

This would enable Sanofi to research and develop a more personalized approach to treatment and identify accompanying technologies to improve results, the statement said.

Headquartered in Paris, the company was formed as Sanofi-Aventis in 2004 by the merger of Aventis and Sanofi-Synthélabo, which were each the product of several previous mergers. It changed its name to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.


It engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops over-the-counter medication.

The company covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur).


Read Also: Sanofi loses German patent case against Amgen over cholesterol drug Praluent



Tags:    
Article Source : With inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News